GLP Watchdog

Drugs and brands

Retatrutide

Every GLP-1 the FDA has approved, and the active ingredient inside each one.

Definition

Eli Lilly's investigational triple agonist (LY3437943), hitting GLP-1, GIP and glucagon receptors. Phase 2 (NEJM 2023, Jastreboff et al., PMID 37366315) reported up to 24.2% weight reduction at 48 weeks. ⚠ The widely quoted 28.7% figure is from TRIUMPH-4 and comes from a Lilly TOPLINE PRESS RELEASE of 11 December 2025 — obesity with knee osteoarthritis, 12 mg, at 68 weeks — not from a peer-reviewed publication; the TRIUMPH papers indexed so far describe the trial DESIGN (PMID 41090431). The same release reported dysesthesia in 20.9% of the 12 mg arm against 0.7% on placebo. Not approved. ⛔ It is sold anyway, as “research peptide”, by sellers this register does not list.

Retatrutide: Lilly's triple agonist evidence →

GLP Watchdog writes these definitions from FDA labels and peer-reviewed PubMed literature. Not one of them is an AI-generated summary.

Other terms under Drugs and brands

Where the evidence lives